Innovus Pharma Expands Exclusive License And Distribution Agreement With Densmore For Zestra To Singapore And Vietnam
Published: Jul 26, 2017
SAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today the signing of an amendment to the exclusive license and distribution agreement with Densmore Pharmaceutical International (“Densmore”), a company based in Monaco, for the commercialization of Zestra® in Singapore and Vietnam.
“We are pleased to expand the commercialization of Zestra® into Southeast Asia to Singapore and Vietnam,” said Innovus Pharma CEO, Dr. Bassam Damaj. “It is very important for us to compete in these two countries in Southeast Asia. While we only announced the Densmore licensing and distribution relationship for France and Belgium in May 2017, we have been very pleased with our collaboration with them and we look forward to growing the business we have with Densmore in the years to come,” continued Dr. Damaj.
Zestra® is currently exclusively partnered with Orimed Pharma, the OTC subsidiary of Jamp Pharma in Canada, DanaLife ApS in select European markets, Sothema Laboratories for the Middle East and North Africa, Elis Pharmaceuticals in Turkey and certain select markets, Luminarie for Australia, New Zealand and the Philippines, BioTask in Malaysia and J&H Co. LTD in South Korea, and non-exclusively to PT Resources in Hong Kong and certain select Asian markets.
Zestra® is currently approved to be commercialized in 34 countries of the world, namely, in Canada, the 28 countries of the European Union, Australia, India, Hong Kong, the United Arab Emirates (“UAE”), South Korea and Morocco. Innovus currently generates revenues from the following markets for Zestra®: Canada, Morocco, certain European countries, South Korea and Hong Kong in addition to the United States as its biggest market.
About Zestra® and FSI/AD
Zestra® is a patented blend of natural oils clinically-proven in double-blind placebo-controlled clinical trials in 276 women to increase in a statistical significant manner the arousal, desire and sexual satisfaction in FSI/AD women. To the Company’s knowledge, Zestra® is the first NHP product to receive approval for the indication of FSI/AD in Canada. To date, no product has been approved to treat FSI/AD, a persistent or recurring inability to attain or maintain adequate sexual excitement until the completion of a sexual activity. The diagnosis can also refer to an inadequate lubrication-swelling response normally present during arousal and sexual activity causing personal distress. Published papers on the FSI/AD market size estimate it to be equal or larger than the market for erectile dysfunction in males, and possibly larger.
Approximately 43% of women in the United States age 18 to 59, or ~50 million, experience some form of Female Sexual Dysfunction (“FSD”) according to a published study1. The FSD market in the United States is estimated to be more than $1 billion per year. For more information on Zestra® visit www.zestra.com.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.fluticare.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.allervarx.com; and www.apeaz.com.
About Densmore Pharmaceutical International
Densmore is based in Monaco and has been in operation since 1946. Its research and development center has about 70 years of expertise in vitamin therapy and micro-nutrition formulas. Since the early 2000's, Densmore has acquired new skills in drugs, medical devices and cosmetics. It received two innovations and research awards for the entire range. In addition to its presence in France, Densmore is exported to many countries in Europe and north Africa. Densmore’s aim is to make available to all, the medical professions and patients, innovative products that combine safety, security and easy to use to meet the health needs and well-being in everyday life. See www.densmore.mc.
Innovus Pharma’s Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from Zestra® in Singapore and Vietnam, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
1 Laumann, E.O. et al. Sexual Dysfunction in the United States: Prevalence and Predictors. JAMA, Feb. 10, 1999. vol. 281, No. 6.537-542 and http://www.indexmundi.com/south_korea/demographics_profile.html.
Innovus Pharma Contact:
Emerging Markets Consulting, LLC
James S. Painter, III